Navigation Links
AVI BioPharma Partner Cook Medical Announces Completion of Patient,Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of,Cardiovascular Disease

PORTLAND, Ore.--(BUSINESS WIRE)--Jul 10, 2007 - AVI BioPharma, Inc. (Nasdaq:AVII) announced today that its partner Cook Medical has completed target patient enrollment and released six-month follow-up data from a Phase II clinical trial known as Appraisal. The trial, currently being held in Germany, was designed to study the effect of the Neugene(R) antisense drug Resten-MP(TM), when used in conjunction with the placement of one or more bare metal stents, in the prevention of cardiovascular restenosis, the narrowing of an artery following a cardiac procedure such as angioplasty.

"We are pleased with the progress our partner Cook Medical has made with our NEUGENE in this trial," said K. Michael Forrest, interim chief executive officer of AVI. "We look forward to continuing our collaboration with Cook Medical as they work to commercialize our technology in the cardiology market."

Cook's release may be viewed on AVI's website at www.avibio.com.

About AVI BioPharma

AVI BioPharma develops therapeutic products for the treatment of life-threatening diseases using third-generation NEUGENE antisense drugs and ESPRIT exon skipping technology. AVI's lead NEUGENE antisense compound is designed to target cell proliferation disorders, including cardiovascular restenosis. In addition to targeting specific genes in the body, AVI's antiviral program uses NEUGENE antisense compounds to combat disease by targeting single-stranded RNA viruses, including West Nile virus, hepatitis C virus, dengue virus, Ebola virus and influenza A virus. AVI's NEUGENE-based ESPRIT technology will initially be applied to potential treatments for Duchenne muscular dystrophy. More information about AVI is available on the company's Web site at http://www.avibio.com.

About Cook Medical

Cook Medical was the first company to introduce interventional devices in the United States. Today, the company participates in all gl
'"/>




Page: 1 2

Related medicine technology :

1. Array BioPharma to Present at the C.E Unterbeg, Towbin Emerging Growth Conference
2. DOR BioPharma Announces Issuance of European Patent for Its Oral Multivalent Botulinum Toxin Vaccine BT-VACC
3. DOR BioPharma Announces Publication Describing Results of Its Multivalent Botulinum Toxin Vaccine BT-VACC
4. Array BioPharma Reports New Clinical Data on Its Anti-Inflammatory Drugs
5. PDL BioPharma Announces Long-Term Nuvion Data Presented at 2007 Digestive Disease Week
6. AVI BioPharma Reports Positive Pre-Clinical Influenza Data
7. Helix BioPharma Corp. Announces Positive Phase II Clinical Results with its Topical Interferon Alpha-2b
8. CeNeRx BioPharma Announces Positive Phase I Results in First Human Trial of Third Generation RIMA Antidepressant
9. Integrated BioPharmas Proprietary Vaccine Technology Achieves Strong Positive Results
10. GenoLogics Announces Bioinformatics Partnership with Illumina
11. Novelos Therapeutics Announces Encouraging Results in Ongoing Phase 2 Ovarian Cancer Trial at Dana-Farber/Partners Cancer Care
Post Your Comments:
(Date:7/31/2014)... VALLEJO, Calif. , July 31, 2014 ... announce it has been selected as the recipient of ... Foundation, which will allow the University to increase research ... is about creating state-of-the-art technology for the study of ... that enhance the diverse needs and interests of our ...
(Date:7/31/2014)... 31, 2014 For its innovative modular Biomedical ... , Art,s-Way Scientific has earned a Modular Building Institute ... in over 30 categories, MBI,s contest is the commercial ... include building manufacturers, dealers, and product and service providers. ... the capability of our team," said Dan Palmer ...
(Date:7/31/2014)... , July 31, 2014 AFFiRiS AG ... York results of AFF008, a Phase I clinical ... the first therapy against the protein alpha-synuclein, a promising Parkinson,s ... J. Fox Foundation for Parkinson,s Research (MJFF) supported the study ... press conference on the impact a disease-modifying therapy would have ...
Breaking Medicine Technology:Touro University California Garners Grant From Long Foundation 2Art's Way Scientific Earns Prestigious Modular Building Institute Award 2Art's Way Scientific Earns Prestigious Modular Building Institute Award 3Art's Way Scientific Earns Prestigious Modular Building Institute Award 4First Clinical Data of Therapeutic Parkinson's Disease Vaccine Encourages Continued Development 2First Clinical Data of Therapeutic Parkinson's Disease Vaccine Encourages Continued Development 3First Clinical Data of Therapeutic Parkinson's Disease Vaccine Encourages Continued Development 4
... a commercial stage private oncology company, announced today ... executives to its Global Commercialization Team.  The Global ... new tumor treating fields (TTF) cancer therapy to ... has joined Novocure as chief commercial officer responsible ...
... (OTCBB: POSC), a leading molecular imaging company specializing in ... today that on December 12, 2011, the Company,s Positron ... approval for sale in Canada. The ... the Attrius systems manufacturer, Neusoft Positron Medical Systems. NPMS ...
Cached Medicine Technology:Novocure Adds Three Senior Oncology Executives to its Global Management Team 2Novocure Adds Three Senior Oncology Executives to its Global Management Team 3Novocure Adds Three Senior Oncology Executives to its Global Management Team 4Positron's Attrius Receives Health Canada Approval 2
(Date:7/31/2014)... NV (PRWEB) July 31, 2014 Weblify has ... after 4 years of development and testing. The result ... monetized websites in as little as 5 minutes without knowing ... full Weblify review , Shane Michaels, an SEO expert, agrees ... quickly. “I’ve seen a lot of web site builders ...
(Date:7/31/2014)... Jeremiah’s Tavern joins ... to create a unique atmosphere and highlight their ... reclaimed barn siding on the exterior ... softwoods flowing throughout the interior as flooring. In ... company New Energy Works Timberframers add ...
(Date:7/31/2014)... Ticket Down is a dependable source ... at the Sun Life Stadium in Miami on Monday, August ... underway. Residents and diehard soccer fans from the Miami, Florida ... International Champions Cup final in person at Sun Life Stadium. ... have been split into two groups where they will then ...
(Date:7/31/2014)... Dr. Mohebi was asked about his experience ... of traveling and sharing what we learned through research ... We are now witnessing results that we never thought ... pleasure to communicate this knowledge to our international colleagues.” ... performing FUE transplantation helped inspire many other doctors to ...
(Date:7/31/2014)... (PRWEB) July 31, 2014 A program ... is coming to the University of Colorado Anschutz ... destination weight loss boot camp and transformation program. ... between AHWC and Eyeworks USA, is an evidenced-based program ... for ABC by Eyeworks USA. This season, the show ...
Breaking Medicine News(10 mins):Health News:Weblify Review Exposes Ricky Mataka And His New Site Building Platform 2Health News:Weblify Review Exposes Ricky Mataka And His New Site Building Platform 3Health News:Popular Tavern Restaurant Features Pioneer Millworks’ Reclaimed Wood in New Locations 2Health News:Guinness International Champions Cup Finals Tickets in Miami, FL Available at Ticket Down 2Health News:Guinness International Champions Cup Finals Tickets in Miami, FL Available at Ticket Down 3Health News:Los Angles Hair Transplant Surgeon, Dr. Parsa Mohebi Inspires Doctors at Global Conferences to Adopt His Novel Method in FUE Hair Transplantation 2Health News:"Extreme Weight Loss: Destination Boot Camp" Comes to Colorado - The CU Anschutz Health and Wellness Center Begins Transformational Program 2Health News:"Extreme Weight Loss: Destination Boot Camp" Comes to Colorado - The CU Anschutz Health and Wellness Center Begins Transformational Program 3
... at work are more likely than long hours, night ... interfere with their sleep. , That,s the conclusion of ... the annual meeting of the Population Association of America. ... approximately 2,300 U.S. adults that monitored the same workers ...
... Antibiotic-Resistant Pathogens Earn Avelox Gold Standard Status Through ... According to a New Report from Decision Resources, ... one of the,world,s leading research and advisory firms ... therapy,s overall clinical efficacy,(defined as cure or improvement ...
... Bionovo Inc.,(Nasdaq: BNVI ) announced today the appointment ... Directors. Dr. Baxter has extensive experience in,academic research as ... in advancing endocrine drugs., "We are very excited ... our,clinical trial programs," said Isaac Cohen, O.M.D., Bionovo,s Chairman ...
... April 17 Eisai Corporation of,North America today ... President of U.S. Corporate Communications. In this newly ... and coordinating,all of Eisai,s corporate communications strategies and ... to Eisai more than 22 years of global ...
... BERKELEY, Calif., April 17 Losing your home to,foreclosure ... loved one. And with so,many Americans facing this dreaded ... in default, according to USA TODAY (Nov. 11,2007) -- ... as,the financial and practical ones., In her seminal ...
... a life,sciences company based in Shanghai, China and ... made several executive management appointments to,build out its ... has joined ProGenTech as its Vice President for ... the global R&D programs,and have accountability for the ...
Cached Medicine News:Health News:U-M study: Work hassles hamper sleep 2Health News:Bayer/Schering-Plough/Shionogi's Avelox Has Advantages Over Levofloxacin in the Treatment of Community-Acquired Pneumonia 2Health News:John D. Baxter, M.D. Joins Bionovo's Board of Directors 2Health News:John D. Baxter, M.D. Joins Bionovo's Board of Directors 3Health News:Eisai Corporation of North America Announces Appointment of Vice President of U.S. Corporate Communications 2Health News:Nolo.com Adds Up the Emotional Costs of Foreclosure With the Five Stages of Foreclosure Grief 2Health News:Nolo.com Adds Up the Emotional Costs of Foreclosure With the Five Stages of Foreclosure Grief 3Health News:ProGenTech Limited Appoints Executive Management Team 2
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
Medicine Products: